A parathyroid hormone (PTH) blood test is an important part of monitoring chronic kidney disease because the kidneys, parathyroid glands, bones, calcium, phosphorus, and vitamin D are tightly connected. As kidney function declines, phosphorus handling becomes less efficient and the kidneys make less active vitamin D. These changes can lower calcium signals and stimulate the parathyroid glands to release more PTH. Over time, this can contribute to secondary hyperparathyroidism and the broader condition called chronic kidney disease–mineral and bone disorder (CKD-MBD).
A high PTH result in CKD does not have one simple meaning. In earlier CKD, clinicians look for a persistent or progressively rising PTH and for correctable factors such as high phosphorus, low calcium, excess phosphate intake, or vitamin D deficiency. In dialysis, a PTH above the normal laboratory range can be expected, and guidelines use a broader target based on multiples of the assay’s upper limit rather than trying to normalize every result. Trends matter more than one isolated value.
- PTH helps assess CKD-related mineral and bone disorder: it is interpreted with calcium, phosphorus, alkaline phosphatase, vitamin D, and kidney function.
- A typical intact PTH reference interval is often around 10–65 pg/mL, but ranges vary by laboratory and assay and should not be self-applied across labs.
- In CKD not on dialysis, a persistently rising or repeatedly high PTH prompts evaluation for modifiable causes rather than automatic treatment to a single numeric target.
- In dialysis, current KDIGO guidance suggests maintaining intact PTH at roughly 2–9 times the assay’s upper normal limit, while avoiding large upward or downward shifts.
- Very high or very low PTH can both be problematic in advanced CKD: high levels may reflect high bone turnover, while over-suppressed PTH can be associated with low-turnover bone disease.
Table of Contents
- What the PTH Test Measures
- Why PTH Rises in Chronic Kidney Disease
- PTH Ranges and Result Meaning
- How PTH Relates to Calcium, Phosphorus, and Vitamin D
- High and Low PTH in CKD
- Testing, Monitoring, and Factors That Affect Results
- What Happens After an Abnormal PTH Result
What the PTH Test Measures
Parathyroid hormone is made by four small parathyroid glands located behind the thyroid gland in the neck. Its main job is to keep calcium and phosphorus in balance. PTH acts on bone and kidneys and indirectly affects the intestines through vitamin D.
Most laboratories use an intact PTH, or iPTH, assay. These assays are designed to measure the full 84-amino-acid hormone, although some PTH fragments can also influence the reported value depending on the method. That matters in kidney disease because reduced kidney clearance can allow PTH fragments to accumulate.
When blood calcium falls, the parathyroid glands increase PTH secretion. PTH then helps raise calcium by increasing calcium release from bone, reducing calcium loss in urine, and supporting production of active vitamin D when kidney function permits. It also promotes phosphorus excretion by the kidneys.
CKD disrupts this system. A lower eGFR means fewer functioning nephrons are available to excrete phosphorus and activate vitamin D. As those changes progress, the parathyroid glands receive repeated signals to produce more PTH.
PTH is therefore not simply a “parathyroid gland test” in CKD. It is also a marker of how the kidneys, skeleton, vitamin D system, and mineral balance are adapting to reduced kidney function.
Why PTH Rises in Chronic Kidney Disease
The rise in PTH usually begins as a compensatory response. The body is trying to keep blood calcium and phosphorus within workable ranges despite declining kidney function.
Several changes contribute:
- the kidneys retain more phosphorus as kidney function declines;
- fibroblast growth factor 23 (FGF23), another phosphorus-regulating hormone, rises early;
- active vitamin D, called calcitriol, falls because damaged kidneys cannot activate vitamin D as effectively;
- less active vitamin D reduces intestinal calcium absorption;
- calcium may fall or remain low-normal;
- the parathyroid glands enlarge and increase PTH secretion over time.
This process is called secondary hyperparathyroidism. “Secondary” means the parathyroid glands are reacting to another problem—in this case CKD and its effects on mineral metabolism—rather than being the original source of disease.
A high phosphorus blood level in kidney disease can intensify this process, but serum phosphorus may remain normal in earlier CKD because PTH and FGF23 are working harder to keep it there. That is why a normal phosphorus result does not necessarily mean mineral metabolism is completely normal.
When secondary hyperparathyroidism persists for years, the glands can become enlarged and increasingly autonomous. In severe cases, especially after long-standing kidney failure, PTH secretion may remain excessive even when the original calcium and phosphorus signals are corrected. This is often called tertiary hyperparathyroidism.
PTH Ranges and Result Meaning
For people without CKD, many intact PTH reference intervals are roughly 10–65 pg/mL, but the exact limits vary by assay. Some laboratories use different units or upper limits. Always interpret the result using the reference range printed on the report.
In CKD, the laboratory reference interval is only the starting point. The desirable PTH level depends on CKD stage, dialysis status, assay method, calcium and phosphorus values, treatment, and the direction of change over time.
| Clinical setting | How PTH is interpreted | Typical concern |
|---|---|---|
| CKD G3a–G5, not on dialysis | No single optimal target is established; trends and persistent elevation matter | Look for high phosphorus intake or level, low calcium, vitamin D deficiency, and worsening CKD |
| CKD G5D, on dialysis | KDIGO suggests approximately 2–9 times the assay’s upper normal limit | Avoid sustained severe elevation and avoid excessive suppression |
| Rapidly rising PTH | More concerning than a stable mildly elevated value | Progressive secondary hyperparathyroidism or worsening mineral imbalance |
| Very low PTH in advanced CKD | May indicate excessive suppression or low bone turnover | Adynamic bone disease risk, especially with calcium or vitamin D treatment |
For example, a PTH of 90 pg/mL may be above a laboratory’s normal range but may not trigger the same response in CKD stage 4 as it would in someone with normal kidney function. Conversely, a value that rises from 100 to 350 pg/mL over several visits may be more meaningful than one isolated result of 350 pg/mL without a prior trend.
The dialysis range is intentionally broad because a completely normal PTH is not always desirable in advanced kidney failure. In dialysis, over-suppressing PTH can reduce bone turnover too much, while persistently very high PTH can drive excessive bone resorption and parathyroid gland growth.
A practical example shows why the assay-specific upper limit matters. If one laboratory lists an upper normal limit of 65 pg/mL, a dialysis range of roughly 2–9 times that limit corresponds to about 130–585 pg/mL. If another assay uses an upper limit of 80 pg/mL, the same guideline concept corresponds to about 160–720 pg/mL. The multiplier is therefore more important than copying a fixed number from another laboratory report.
It is also possible for two patients with the same PTH to have different bone turnover. Skeletal responsiveness to PTH varies in CKD, and some patients develop relative resistance to the hormone. This is one reason PTH is useful as a trend and risk marker but is not a perfect substitute for direct assessment of bone. Bone-specific alkaline phosphatase can add information, and in selected complex cases a bone biopsy may be considered when the result would change treatment.
Clinicians also pay attention to the direction and speed of change. A gradual rise over several years as CKD progresses may reflect the expected evolution of secondary hyperparathyroidism. A much faster rise over a few months can prompt a closer look at phosphorus control, vitamin D status, adherence to prescribed therapy, or a recent loss of kidney function. Likewise, a sharp fall after treatment can be desirable if PTH was very high, but an excessive drop may raise concern for over-suppression.
How PTH Relates to Calcium, Phosphorus, and Vitamin D
PTH should almost never be interpreted alone in CKD. The meaning becomes clearer when it is read beside calcium, phosphorus, vitamin D, and alkaline phosphatase.
Calcium
Low or low-normal calcium stimulates PTH secretion. In CKD, low active vitamin D can reduce calcium absorption from the intestine. Some medications and dialysis prescriptions can also change calcium levels. A renal function panel often includes calcium and phosphorus, giving useful context for PTH.
High calcium with high PTH points toward a different pattern. It can occur with tertiary hyperparathyroidism or with primary hyperparathyroidism unrelated to CKD. Clinicians may need to distinguish between these possibilities using history, kidney stage, prior PTH trends, vitamin D status, medications, and sometimes imaging.
Phosphorus
Phosphorus retention is a major driver of CKD-MBD. PTH tries to increase phosphorus excretion, but as kidney function declines, the kidneys become less able to respond. High phosphorus can then persist despite high PTH.
Dietary phosphorus source matters. Phosphate additives in processed foods are highly absorbable, while phosphorus from many plant foods is less bioavailable. However, phosphorus restriction should be individualized, especially because overly restrictive diets can reduce protein and overall nutrition.
Vitamin D
Two forms are important. 25-hydroxyvitamin D reflects vitamin D stores and is the usual test for deficiency. 1,25-dihydroxyvitamin D, or calcitriol, is the active form produced largely by the kidneys. CKD can reduce calcitriol even when 25-hydroxyvitamin D is adequate.
Low vitamin D status can worsen secondary hyperparathyroidism. Correcting vitamin D deficiency may help lower PTH in some patients, but active vitamin D medicines require careful monitoring because they can raise calcium and phosphorus.
Alkaline phosphatase
Alkaline phosphatase, especially bone-specific alkaline phosphatase when available, provides another clue about bone turnover. Very high PTH plus elevated bone turnover markers can support concern for high-turnover renal bone disease, while low PTH may suggest low turnover. PTH is an imperfect proxy for actual bone histology, so it should not be treated as a direct measurement of bone turnover.
High and Low PTH in CKD
A high PTH value is common as CKD advances, but the reason and severity determine what it means.
What high PTH can mean
High PTH in CKD most often reflects secondary hyperparathyroidism. Common contributors include:
- declining GFR;
- high phosphorus or excessive absorbed phosphorus;
- low calcium;
- vitamin D deficiency;
- reduced calcitriol production;
- long-standing parathyroid gland enlargement;
- poor control of CKD-MBD over time.
Persistently severe elevation can contribute to high-turnover bone disease, bone pain, fractures, and skeletal deformity. CKD-MBD is also associated with vascular and soft-tissue calcification, although PTH is only one part of that broader process.
High PTH does not automatically mean a person needs a PTH-lowering drug. In non-dialysis CKD, guideline-based management begins by looking for correctable factors and following trends. In dialysis, treatment decisions may involve calcimimetics, calcitriol, vitamin D analogues, phosphorus management, or parathyroid surgery in severe refractory cases.
What low PTH can mean
Low PTH in advanced CKD is not always reassuring. PTH can become too suppressed after intensive treatment with calcium-containing binders, active vitamin D, or calcimimetics. Some patients also have diabetes, malnutrition, inflammation, or other factors associated with low bone turnover.
Low bone turnover in CKD is often called adynamic bone disease. Bone remodeling is reduced, which can impair the skeleton’s ability to incorporate calcium and may increase fracture risk. This is one reason clinicians avoid treating every patient toward a “normal” PTH without considering CKD stage.
Testing, Monitoring, and Factors That Affect Results
PTH testing requires a blood sample from a vein. Fasting is not always required, but the ordering clinician or laboratory may request specific preparation when calcium, phosphorus, vitamin D, or other tests are drawn at the same time.
PTH is biologically and analytically variable. Results can change because of:
- different PTH assay platforms;
- the time between blood collection and laboratory processing;
- short-term calcium and phosphorus changes;
- vitamin D treatment;
- calcimimetic medicines;
- dialysis timing;
- parathyroid surgery;
- progression or recovery of kidney function.
For this reason, serial values are most useful when they come from the same laboratory method whenever possible. A sudden change after switching laboratories may partly reflect assay differences.
Context around the blood draw also matters. In people receiving dialysis, calcium and phosphorus can shift with the treatment schedule, so clinicians often try to compare samples collected at similar points in the dialysis cycle. A recent change in calcium supplements, phosphate binders, active vitamin D, or a calcimimetic can also alter the pattern before a new steady state is reached. If a result looks unexpectedly different from prior values, repeating the test and reviewing recent medicines, supplements, dialysis timing, and kidney function can be more useful than reacting to one isolated number. This approach helps separate a true biological change from short-term variation or a testing difference.
Monitoring frequency depends on CKD stage and whether results are abnormal. Testing generally becomes more frequent as kidney function declines or when PTH, calcium, or phosphorus is changing. CKD-MBD monitoring usually begins by CKD stage G3a and becomes much closer in stage G4, stage G5, and dialysis.
Guideline-based intervals are flexible rather than rigid. In stable stage G3a–G3b CKD, calcium and phosphorus may be checked about every 6–12 months, while PTH timing is guided by the starting level and CKD progression. In stage G4, calcium and phosphorus are often checked every 3–6 months and PTH every 6–12 months. In stage G5 or dialysis, calcium and phosphorus are commonly checked every 1–3 months and PTH every 3–6 months. Abnormal results, treatment changes, pregnancy, transplant status, or rapidly changing kidney function may justify more frequent testing.
The PTH trend should also be interpreted with a kidney function blood test panel because an abrupt decline in kidney function can quickly change phosphorus handling and mineral balance.
What Happens After an Abnormal PTH Result
An abnormal PTH result usually leads to a pattern review, not a decision based on PTH alone. The clinician may check or review calcium, phosphorus, alkaline phosphatase, 25-hydroxyvitamin D, eGFR, medications, dialysis prescription, dietary phosphorus exposure, and prior PTH values.
If PTH is progressively rising in non-dialysis CKD, common next steps include correcting vitamin D deficiency when appropriate, addressing persistently high phosphorus, reviewing calcium balance, and reassessing the trend. Routine use of active vitamin D analogues is not recommended for every adult with non-dialysis CKD; they are generally reserved for selected patients with severe or progressive secondary hyperparathyroidism.
In dialysis, treatment is individualized to PTH, calcium, phosphorus, bone turnover risk, symptoms, and prior therapy. Large changes in PTH within the broad target range may prompt action before the value moves far outside it. This trend-based approach is more useful than waiting for a single dramatic number.
Persistent severe hyperparathyroidism despite medical therapy may lead to consideration of parathyroidectomy. Surgery is generally reserved for selected patients because it can produce major shifts in calcium and bone metabolism and requires close postoperative monitoring.
Urgent care is rarely triggered by PTH itself. Instead, urgency comes from associated problems such as severe hypercalcemia, severe hypocalcemia, dangerous phosphorus abnormalities, arrhythmia symptoms, confusion, seizures, or other signs of major electrolyte disturbance.
The central point is that PTH in kidney disease is a context marker. It helps show how mineral metabolism is adapting or becoming maladaptive as CKD progresses. The best interpretation uses the direction of change, not just whether the result is printed in red on a laboratory report.
References
- Secondary hyperparathyroidism in chronic kidney disease: update on pathophysiology and new treatment targets 2026 (Review)
- Pathophysiology and therapies of CKD-associated secondary hyperparathyroidism 2025 (Review)
- Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs 2024 (Review)
- Secondary hyperparathyroidism in chronic kidney disease: A narrative review focus on therapeutic strategy 2024 (Review)
- CKD-Mineral and Bone Disorder (CKD-MBD) 2017 (Guideline)
Disclaimer
PTH targets in chronic kidney disease depend on CKD stage, dialysis status, the specific assay, calcium and phosphorus values, treatments, and trends over time. Do not change phosphate binders, vitamin D products, calcimimetics, calcium supplements, or dialysis treatment based on a single PTH result without clinical guidance. A qualified healthcare professional should interpret PTH together with the broader CKD-MBD picture.
